Segmental bone defects, particularly in injured military personnel and the aging population, reduce health-related quality of life and result in significant healthcare costs. KeraNetics is developing a controlled release carrier system capable of providing physiologically relevant doses of bone growth factors.
In pre-clinical models, this system has demonstrated superior bone repair and regeneration compared to currently available treatments. For example, the delivery vehicle for bone growth factor showed improved released kinetics compared to market leaders. In addition, degradation rates and release profiles can be tailored to match a variety of regenerating bone types.